Donald Abrams, M.D., Chief of Hematology and Oncology at San Francisco General Hospital, co-authored *Integrative

Donald Abrams, M.D., Chief of Hematology and Oncology at San Francisco General Hospital, co-authored *Integrative Oncology*. A pioneer in medical cannabis research, he has extensive experience with cancer and HIV/AIDS patients.

The U.S. government classifies cannabis as a Schedule I drug—the most restricted category—asserting it is unsafe with no accepted medical use.

Despite this, medical cannabis has been used for millennia, with no reported overdoses. Moreover, recent global clinical research consistently demonstrates its medicinal value.

On April 28, 2012, the Seventh National Clinical Conference on Cannabis Therapeutics, hosted by Patients Out of Time, featured Andrew Weil, MD. Dr. Weil, founder and director of the Arizona Center

On April 28, 2012, the Seventh National Clinical Conference on Cannabis Therapeutics, hosted by Patients Out of Time, featured Andrew Weil, MD. Dr. Weil, founder and director of the Arizona Center for Integrative Medicine at the University of Arizona, discussed the challenges and future of natural cannabis and cannabinoids in modern medicine.

His presentation highlighted therapeutic benefits such as cannabis's opioid-sparing effect, spasticity relief, and neurological advantages for conditions like MS and ALS. He also addressed its role in modulation and improving quality of life. Following his talk, panel moderator Clint Werner questioned Dr. Weil about his early research into cannabis.